Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A.

Michael Bullano, Christina Cool,Bob G Schultz,Sneha Durgapal,Naomi Sacks,Yanmei Liu,Rebecca Kee,Katharine Batt

Expert review of pharmacoeconomics & outcomes research（2023）

引用 0|浏览1

暂无评分

摘要

While there may be higher reimbursement for rpFVIII hospitalizations, this analysis suggests that the use of rpFVIII, compared to rFVIIa, may have no impact on hospital finances for the majority of hospitals, despite rpFVIII's higher per unit cost.

查看译文

关键词

Acquired hemophilia,bypassing agents,cost-to-charge ratio,financial impact,hospital charges,hospital costs,hospital finances,hospital revenue,medicare,rare disease,recombinant porcine FVIII

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要